The Lundqusit Institute (formerly LA BioMed) is an independent non-profit research institute located in the South Bay region of Los Angeles on a 72-acre campus shared with the Harbor-UCLA Medical Center.

The Lundqusit has over 100 principal investigators and 400 researchers in total, a translational focus, and its innovations have led to 600 issued and pending patents and thirteen start-up companies.

We obtain ~$70,000,000 each year in NIH grant funding and sponsored research and our technologies have helped to generate numerous global breakthroughs:

• The cholesterol test
• The US paramedic model
• FDA 510k-cleared revolutionary heart monitoring medical device by QT Medical
• FDA-approved drug Aldurazyme® for Mucopolysaccharidosis BioMarin/Sanofi)
• FDA-approved drug (with UCLA) to treat submental fullness (Kybella®, Allergan)
• FDA-approved drug for the treatment of pain associated with sickle-cell anemia (Endari®, Emmaus)

Session ID: 555386